Sucralfate and colloidal bismuth subcitrate (CBS) have both been shown to protect gastroduodenal mucosa against experimental damage'`3 and to heal peptic ulcers in man. [4] [5] [6] [7] Neither agent effects acid secretion89 and their mechanisms of ulcer healing and mucosal protection remain unclear.
Sucralfate, a basic aluminium salt of sucrose octasulphate, was originally proposed to act by adhering to damaged and ulcerated tissue thereby forming a physical barrier against injury by luminal acid, pepsin and bile salts.IO'2 More recent studies indicate that this drug has additional actions on gastroduodenal mucosa which may contribute to its protective effect. For example, sucralfate has been reported to stimulate prostaglandin generation,'3 bicarbonate secretion,'4 and mucus production'" in laboratory animals.
Colloidal bismuth subcitrate precipitates in the acidic environment of the stomach which would encourage binding to the mucosal surface in a similar manner to sucralfate. In addition to the formation of a physical barrier, this adherence could also initiate an irritant reaction which would lead to the reported formation and release of endogenous prostaglandins.'6"' Clinical interest in colloidal bismuth subcitrate (De-Nol@R, Gist-Brocades) has recently been aroused by reports of lowered duodenal ulcer relapse rates in comparison with H2 receptor antagonists.'81'0 The reasons for this are unclear although the bactericidal action of bismuth against Campylobacter pylori is the currently favoured hypothesis. 21 The present studies were designed to evaluate the actions of sucralfate and colloidal bismuth subcitrate on mucosal bicarbonate secretion in the rat duodenum and human stomach.
Methods

ANIMALS
Experiments were performed using female Sprague-Dawley rats (200-220 g body weight) obtained from ICI Pharmaceuticals animal breeding unit. Rats were starved for 20-24 hours before use in cages with wide mesh bottoms to prevent coprophagy but allowed free access to drinking water.
Measurement ofsecretion
Duodenal bicarbonate secretion was measured as previously described. 22 Measurement ofsecretion Gastric bicarbonate secretion by the intact human stomach was measured by an intubation method described previously.2' After an overnight fast the volunteers swallowed a multilumen polyethylene tube which was positioned by fluoroscopy with its tip in the second or third part of the duodenum. Ranitidine (150 mg orally one hour beforehand and 25 mg/h iv during the study) was given to maintain intragastric pH between 6 and 7. Saliva was continuously removed by suction which reduced salivary contamination to below 3% of measured gastric bicarbonate. After aspiration of resting gastric contents, the stomach and duodenum were perfused at 2 ml/min with saline containing 12 5 tCi/l of 3H-polyethylene glycol and '4C-polyethylene glycol respectively. Aspirates were collected by continuous suction at 10 minute intervals from the antrum and duodenum for measurement of marker concentration. Aliquots (1 ml) were frozen for later assay of PGE2 concentration. In the middle of each sampling period a separate 1 ml aliquot was aspirated into a cooled syringe for immediate determination of pH and pCO2. (Fig 1) . The preparation responded to topical PGE2 (10 pg/ml) which induced a peak stimulation of 110% from 6-60 (1-65) to 15-4 (2 63) !tmol/cm/h (p<001, n=5).
Similarly, intravenous administration of 10 Rtmol/kg had no effect on alkalinisation while topical PGE2 (10 tg/ml) increased secretory rate by 120% from 4 30 (0 60) to 9 0 (1 56) iimol/cm/ h (p<001, n=6) (Fig 1) . This dose of colloidal bismuth subcitrate was without effect on dimaprit stimulated gastric acid secretion in the rat over a two hour period (acid secretion= 174 (14) [tmol in controls and 182 (19) iimol in treated animals, p>0 1, n=10). When the higher dose of colloidal bismuth subcitrate (100 imol/kg (117 g/kg)) was administered systemically, all the animals died.
Sucralfate
Sucralfate induced two distinct responses depending upon basal secretory rate. Topical application of sucralfate 1 mg/kg to rats with high rates of basal alkali secretion (>3 [tmol/cm/h, n=4) had no effect on alkali secretion. Thus 40 secretory rate during drug exposure (5 45 (1-30) [tmol/cm/h) was similar to that during the basal re period (5 55 (1F36)) although PGE2 (10 Rg/ml) al stimulated secretion by 90% from 4 90 (1-17) to th 9g30 (1 31) ,tmol/cm/h, p<005 (Fig 2) .
In the animals with low basal alkali secretion (<3 iimol/cm/h, n=4) topical sucralfate produced a rise in alkali secretion of 175% from 1 20 1-(0 33) to 3-3 (0-97) .tmol/cm/h, p<005. These preparations appeared more sensitive to PGE2 d which increased secretory rate by 460% over the l. initial basal value (from [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] (0 33) to 7T0 (1-85) 4 [tmol/cm/h, p<0 05). 
Results
ANIMAL STUDIES
Bismuth subcitrate Topical application of 10 and 100 jimol colloidal bismuth subcitrate had no effect on alkali secre- (Fig 3) . (Table) .
Sucralfate
During perfusion of the stomach with 1 g sucralfate over one hour there was a significant increase in alkali secretion from 494 (74) to 741 (88) [tmol/h (n=8, p<0-01) which returned towards basal values when the drug containing suspension was replaced by PEG during the third hour (Fig 3) . There was no change in bicarbonate originating from duodenogastric reflux during the three study periods. There carbonate secretion or luminal PGE2 output in therapeutically relevant doses. These findings are at variance with a previous study in which stimulation of bicarbonate secretion was observed in man and dogs with similar concentrations of bismuth subcitrate.24 Stimulation of bicarbonate secretion by colloidal bismuth subcitrate has also been reported in studies on isolated amphibian gastric and duodenal mucosae by a mechanism independent of the local generation and release of prostaglandins.29 While our present study provides a clear demonstration that colloidal bismuth subcitrate has no effect on gastroduodenal bicarbonate secretion, the overall data from in vivo studies is conflicting.
In contrast with findings with colloidal bismuth subcitrate, therapeutic doses of sucralfate stimulated both human gastric and rat duodenal alkalinisation. In the human stomach there was a delayed rise in luminal PGE2 output. The temporal dissociation between stimulation of gastric luminal alkalinisation and increased lumina PGE2 output suggests that the two phenomena may not be linked, particularly as only the bicarbonate increase was coupled to volume flow. This is reinforced by the finding that pretreatment with the cyclooxygenase inhibitor indomethacin failed to prevent stimulation of bicarbonate secretion by sucralfate although stimulation of luminal PGE2 output was blocked. These observations support earlier in vitro experiments which showed that sucralfate induced alkali secretion was not inhibited by indomethacin pretreatment of amphibian gastric mucosa. 4 A similar finding has been reported in respect of stimulation of mucus production by sucralfate.
II
It is possible that sucralfate acts on the (prostaglandin-independent) Cl-/HCO3-exchange component of duodenal alkali secretion. This contention is reinforced by the fact that sucralfate stimulates alkali secretion in the stomach where anion exchange is thought to be the major mechanism of HCO3-transport. 26 If, in the group of rats with high basal alkali secretion, Cl-/HCO3-exchange is operating maximally then an agent stimulating such exchange would be expected to show little or no effect on bicarbonate output whereas an agent stimulating electrogenic secretion such as PGE2 would remain effective. Such an explanation is consistant with our results which show that high basal secretion in the duodenum is associated with a response to PGE2 but not sucralfate while low basal secreting preparations responded to both sucralfate and PGE2.
These observations raise the intriguing possibility that sucralfate may act in three separate ways. First, by adhering to ulcerated mucosa it may produce a physical barrier to luminal acid and pepsin. Second 
